On June 22, the 3rd Zhejiang Red Ribbon & 2025 Yangtze River Delta Regional Conference on AIDS, Sexually Transmitted Diseases (STDs), and Hepatitis C concluded successfully in Jinhua, Zhejiang Province. Focused on HIV/AIDS, STDs, and hepatitis C, the conference convened keynote addresses and panel discussions across prevention, control, clinical diagnosis, and treatment. Experts shared cutting-edge advancements and explored innovative solutions.      

    Professor Han Mengjie, Chief Expert on AIDS Prevention and Control at the Chinese Center for Disease Control and Prevention (China CDC), reported on China’s HIV/AIDS epidemic and prevention efforts. As of the end of 2024, 1.355 million HIV/AIDS survivors were reported, with continuously increasing antiretroviral therapy (ART) coverage. Among the three 95% targets for 2024, the HIV detection rate reached 84.5% 3. Professor Zhang Fujie from Beijing Ditan Hospital Affiliated to Capital Medical University highlighted challenges in HIV treatment, including low drug resistance and viral load testing coverage—only 43% of patients received baseline viral load testing. The 2024 Guidelines for the Diagnosis and Treatment of AIDS emphasize that HIV-1 nucleic acid quantification testing plays a critical role in monitoring ART efficacy, guiding treatment adjustments, and serving as a supplementary nucleic acid test 10.Director Jin Cong from China CDC’s National Center for AIDS/STD Control and Prevention discussed advancements in HIV testing technologies, noting that HIV nucleic acid testing as a supplementary assay streamlines diagnosis and treatment initiation.

            

    Shandong Jianwei's HIV-1 RNA viral load detection solution combines high-sensitivity reagents with automated equipment to support AIDS prevention, treatment, and clinical management. It offers low-to-medium throughput, high-throughput, and integrated machine solutions to meet diverse application scenarios.